Loading
A blood test that tracks lymphoma DNA far below what a PET scan can see, so doctors can tell early who is cured and who will relapse.
Phased variant enrichment and detection sequencing (PhasED-seq, Foresight CLARITY) detects lymphoma ctDNA to parts-per-million by tracking multiple mutations on the same DNA fragment. End-of-treatment undetectable ctDNA predicts cure in DLBCL better than PET in several cohorts; ctDNA-guided escalation and de-escalation trials are opening. clonoSEQ tracks the clonal immunoglobulin rearrangement.
Deep sequencing of plasma cell-free DNA for tumour-specific mutations or the clonal IG rearrangement, with error suppression via phased variants.
One technology page on OnCo cites this paper by its DOI; this record gives the citation a page of its own so a reader can follow it without leaving OnCo. Read the abstract above alongside the citing page listed under Related; the record was created automatically from the Europe PMC entry and its figures have not been checked by hand.
One technology page and one idea page on OnCo cite this paper by its DOI; this record gives the citation a page of its own so a reader can follow it without leaving OnCo. Read the abstract above alongside the citing pages listed under Related; the record was created automatically from the Europe PMC entry and its figures have not been checked by hand.
Query for this technology: (TITLE:"ctDNA monitoring in lymphoma" OR ABSTRACT:"ctDNA monitoring in lymphoma" OR TITLE:"PhasED-seq, clonoSEQ" OR ABSTRACT:"PhasED-seq, clonoSEQ") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about ctDNA monitoring in lymphoma (PhasED-seq, clonoSEQ), not a curated reading list.
Shares Enhanced detection of minimal residual disease by targeted sequencing of phased variants in circulating tumor DNA, Circulating Tumor DNA Measurements As Early Outcome Predictors in Diffuse Large B-Cell Lymphoma, Early-stage classical Hodgkin lymphoma (stage I to II), Dormant cells and minimal residual disease.
Shares Enhanced detection of minimal residual disease by targeted sequencing of phased variants in circulating tumor DNA, Circulating Tumor DNA Measurements As Early Outcome Predictors in Diffuse Large B-Cell Lymphoma, Dormant cells and minimal residual disease, Minimal / molecular residual disease (MRD).
Shares Dormant cells and minimal residual disease, Minimal / molecular residual disease (MRD), Circulating tumour DNA (ctDNA), MRD / molecular residual disease testing.
Shares Foresight Diagnostics, Dormant cells and minimal residual disease, Minimal / molecular residual disease (MRD), Circulating tumour DNA (ctDNA).
Shares ctDNA MRD positivity (molecular residual disease after curative treatment), Minimal / molecular residual disease (MRD), Circulating tumour DNA (ctDNA), MRD / molecular residual disease testing.
Shares Dormant cells and minimal residual disease, Minimal / molecular residual disease (MRD), Circulating tumour DNA (ctDNA), MRD / molecular residual disease testing.
Shares ctDNA MRD positivity (molecular residual disease after curative treatment), Minimal / molecular residual disease (MRD), Circulating tumour DNA (ctDNA), MRD / molecular residual disease testing.
Shares Foresight Diagnostics, Dormant cells and minimal residual disease, Minimal / molecular residual disease (MRD), MRD / molecular residual disease testing.